Emerging Company Showcase 2021

Innovative, Fundable, Early Stage Opportunities

Each company featured in the Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who asked questions about their science and strategy. 

Presenting Companies

	3Helix, Inc., Salt Lake City, UT: Commercializing labeled collagen hybridizing peptide (CHP) that specifically binds to such unfolded collagen chains, enabling unlimited laboratory applications in pathology, biomechanics, cell biology, regenerative medicine, and more
	Avenzoar Pharmaceuticals, Encinitas, CA: Developing oncology drugs aimed at targeting and inhibiting mechanisms of metastasis and drug resistance with an initial focus on pancreatic cancer.
	Axonis, Cambridge, MA: Advancing a pipeline of neuron-reviving therapeutics which enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration; restore excitation/inhibition balance; and regenerate.
	BriOri Biotech, Carlsbad, CA: Addressing the osteoarthritis treatment problem with a novel topical reformulation of rofecoxib with low systemic exposure.
	Calder Biosciences, Inc., Brooklyn, NY: Developing novel vaccines for respiratory syncytial virus (RSV) and Influenza.
	Cayuga Biotech, Bridgewater, NJ: Developing treatments that accelerate the body’s natural clotting response for bleeding episodes in patients with compromised platelet function.
	CMTx Biotech, Kings Park, NY: Developing a clinical-stage, orally-administered, small molecule drug candidate for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome and acute respiratory distress syndrome, including from SARS-CoV-2 infection (COVID-19).
	Concarlo Holdings, Brooklyn, NY: Developing therapeutics to treat metastatic breast cancer alongside a diagnostic to identify patients who will respond to therapy.
	Early Diagnostics Inc., Los Angeles, CA: Developing non-invasive liquid biopsy tests for early cancer detection and precision medicine.
	Enalare Therapeutics Inc., Princeton, NJ: Developing novel therapies for patients suffering from life-threatening critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity.
	ENB Therapeutics, New York, NY: Developing therapies targeting drug-resistant cancers including melanoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.
	Escend Pharmaceuticals, Inc., Menlo Park, CA: Developing oncology therapeutics which ablate cancer cells focused on orphan indications including acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and triple negative breast cancer (TNBC).
	EVQLV, New York, NY: Develops artificial intelligence engineered with life science data to accelerate how biologic therapies reach those in need.
	Forkhead BioTherapeutics Inc., New York, NY: Developing an oral therapy for insulin-dependent diabetes to convert cells in the gut into glucose responsive insulin producing cells.
	Hillhurst Biopharmaceuticals, San Diego, CA: Developing a pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pain.
	ImmunogenX, Inc., Newport Beach, CA: Developing therapeutic treatment for patients with celiac disease.
	Jaan Biotherapeutics, San Diego, CA: Developing therapies to activate the cardiac regeneration process in diseased hearts.
	JBS Science, Doylestown, PA:  Developing enhanced methods for cell-free DNA isolation and qPCR assays for identifying tumor DNA biomarkers in urine and blood.
	Lohocla Research Corporation, Aurora, CO: Developing a non-opiate small molecule for treating chronic pain.
	MarPam Pharma, Oakdale, MN: Developing a one-time treatment for the durable remission of HIV using a patient’s own T cells to express a chimeric antigen receptor (CAR).
	Medosome Biotec, Alachua, FL: Developing a genetic test to establish safe dosing regimens for treating mitochondrial disorders; enhanced screening methods for muscular dystrophy drug candidates; a modified oral rehydration solution to prevent diarrhea.
	MenoGeniX, Aurora, CO: Developing a biopharmaceutical alternative to FDA-approved hormone therapies and anti-depressants to treat hot flashes and related vasomotor symptoms of naturally occurring and surgically induced menopause.
	MyoGene Bio, LLC, Los Angeles CA: Developing gene editing platform to permanently address the underlying cause of the disease for half of all Duchenne patients.
	Nervive, Mayfield Heights, OH: Developing a noninvasive, magnetic stimulation treatment for emergency treatment for strokes.
	NomoCan Pharmaceuticals, New York, NY: Developing a monoclonal antibody selectively identify and diagnose pancreatic cancer.
	Novomedix, San Diego, CA: Developing small molecules for the treatment of metastatic triple negative breast cancer (mTNBC).
	Obsidio, Inc., Columbia, SC: Developing a minimally-invasive embolic agent using a shear-thinning biomaterial technology.
	PathoVax, Baltimore, MD: Developing RGVax™, a comprehensive HPV vaccine that aims to target all clinically relevant HPVs (oncogenic and non-oncogenic).
	Pelex, New York, NY: Developing a therapeutic device to strengthen muscles and nerves of the pelvic floor to treat pelvic floor disorders (PFDs).
	Quench Medical, Saint Paul, MN: Developing a novel aerosol platform technology to deliver medicine into deep areas of the lung with an initial focus on the treatment of lung cancer.
	Qx Therapeutics, Branford, CT: Developing therapies to treat acute lung injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) via inhibition of MAP3K2/3.
	Rumi Scientific, New York, NY Developing a high-throughput organoid-like platform that mimics the development of the human brain to predict the therapeutic effect of drugs.
	SeeTrue Technology, Rockville, MD: Developing a line of microcapillary, easy-to-use needles that improve precision and outcomes of microinjections.
	Sen-Jam Pharmaceutical, Huntington NY: Developing therapeutics to address opioid use disorder, viral respiratory infections due to coronaviruses such as COVID-19 and other inflammation and toxin-induced conditions.
	SiVEC Biotechnologies, Fort Collins, CO:  Developing delivery platform using non-pathogenic bacteria for targeted intracellular delivery of nucleic acid drugs and vaccines to mucosal epithelial cells.
	SoleStim, San Francisco, CA: A Non-Invasive Neuromodulation Device for In-Home Treatment of Overactive Bladder
	SomaGenics, Santa Cruz, CA: Developing combination sshRNA-and antimiR- based therapy targets the hypoxia response pathway which is critical to normal wound healing.
	South Rampart Pharma, New Orleans, LA: Developing a new class of small molecule, non-opioid pain medicines.
	Tellus Therapeutics, Research Triangle Park, NC: Developing therapies for the treatment of Perinatal white matter injury.
	Xenimmune, New York, NY: Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
	View the 2020 showcase presenters here.